http://semillasdefe.com/index.php?option=com_content&view=article&id=44&Itemid=61
Palo Alto-based PrognosDx did not disclose terms ofthe deal. “We are excited by the opportunity to buildxon UCLA’s successes,” said Kamranh Tahamtanzadeh, president and CEO of PrognosDc Health. “The products that are beingf developed as part of this license address the urgeny need for more accurate diagnostic and prognostic testsw utilizing predictive histone biomarkers as well as identifying thosde patients who need chemotherapy and most likely respondc to particularcancer therapies.” The technologyy PrognosDx will use is in the field of epigenetics — the studyg of changes in cell behavior that are not encodes in the sequence of DNA.
In cancer cells, numerous alterations in DNA methylation and histone modificationss havebeen identified. PrognosDx Health is focused on improving the treatmenty of cancer and other complex diseases bydeveloping semi-quantitativee and quantitative laboratory products based on globakl histone modification patterns. The company is profilesd in the Business Journal thisweek in
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment